nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

27.02.2018 | Original Article – Clinical Oncology

Ablative dual-phase Erbium:YAG laser treatment of atrophy-related vaginal symptoms in post-menopausal breast cancer survivors omitting hormonal treatment

verfasst von: A. R. Mothes, M. Runnebaum, I. B. Runnebaum

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

First evaluation of dual-phase vaginal Er:YAG laser to omit hormonal treatment for atrophy-related symptoms in post-menopausal breast cancer survivors following prolapse surgery.

Methods

Patients with a history of breast cancer at the time of surgery for pelvic organ prolapse were offered non-hormonal vaginal Er:YAG laser treatment when complaining of atrophy-related genitourinary syndrome of menopause. A single 10-min course of dual-phase protocol of pulsed Er:YAG laser (2940 nm, fractional ablative and thermal mode, fluence according to tissue thickness). Follow-up included subjective satisfaction, vaginal pH, vaginal health index (VHI), and complications after 6 weeks.

Results

A total of 16 breast cancer survivors (age 71 years, SD 7) had been seeking treatment for pelvic floor symptoms related to vaginal atrophy at follow-up visits after prolapse surgery. All ablative vaginal Er:YAG laser outpatient procedures were successfully completed, all patients returned to daily activities without a need for analgetic medication. Evaluation was performed after 8.3 (SD 2.5) weeks. Pre-laser VHI scored 16 (SD 4.6) and post-laser VHI 20 (SD 3) with p = 0.01. Patients were satisfied in 94% (n = 15) regarding symptom relief.

Conclusions

Breast cancer survivors with atrophy-related complaints after pelvic floor surgery may benefit from vaginal application of this innovative dual protocol of Er:YAG laser technology as a non-hormonal treatment approach.

Alexiades-Armenakas MR, Dover JS, Arndt KA (2012) Fractional laser skin resurfacing. J Drugs Dermatol 11:1274–1287PubMed

Bachman GA, Noeyolitz M, Kelly SL (1992) Long-term non-hormonal treatment of vaginal dryness. Clin Pract Sex 8:3–8

Berga SL (2013) Profile of ospemifene in the breast. Reprod Sci 20:1130–1136. https://doi.org/10.1177/1933719113497290 CrossRefPubMed

Biglia N, Bounous VE, Sgro LG, D’Alonzo M, Pecchio S, Nappi RE (2015) Genitourinary syndrome of menopause in breast cancer survivors: are we facing new and safe hopes? Clin Breast Cancer 15:413–420. https://doi.org/10.1016/j.clbc.2015.06.005 CrossRef

Biglia N, Bounous VE, D’Alonzo M, Ottino L, Tuninetti V, Robba E, Perrone T (2017) Vaginal atrophy in breast cancer survivors: attitude and approaches among oncologists. Clin Breast Cancer. https://doi.org/10.1016/j.clbc.2017.05.008 (Epub ahead of print)PubMed

Brubaker L, Shull B (2005) EGGS for patient-centered outcomes. Int Urogynecol J Pelvic Floor Dysfunct 16:171–173CrossRefPubMed

Buchholz S, Mögele M, Lintermans A, Bellen G, Prasauskas V, Ortmann O, Grob P, Neven P, Donders G (2015) Vaginal estriol–lactobacilli combination and quality of life in endocrine-treated breast cancer. Climacteric 18:252–259. https://doi.org/10.3109/13697137.2014.991301 CrossRefPubMed

Bump RC, Mattiasson A, Bo K, Brubaker LP, DeLancey JO, Klarskov P et al (1996) The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol 175:10–17CrossRefPubMed

Cook ED, Iglehart EI, Baum G, Schover LL, Newman LL (2017) Missing documentation in breast cancer survivors: genitourinary syndrome of menopause. Menopause https://doi.org/10.1097/GME.0000000000000926. (Epub ahead of print)PubMed

Dmovsek-Olup B, Beltram M, Pizern J (2004) Repetitive Er:YAG laser irritation of human skin: a histological evaluation. Lasers Surg Med 35:146–151CrossRef

Donders G, Neven P, Moegele M, Lintermans A, Bellen G, Prasauskas V, Grob P, Ortmann O, Buchholz S (2014) Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat 145:371–379. https://doi.org/10.1007/s10549-014-2930-x CrossRefPubMedPubMedCentral

European Medicines Agency (2015). http://www.ema.europa.eu/ema. Assessment report EMA/78875/2015

Fisher JC (1992) Photons, physiatrics, and physicians: A practical guide to understanding laser light interaction with living tissue, part 1. J Clin Laser Med Surg 10:419–426PubMed

Gambacciani M, Palacios S (2017) Laser therapy for the restoration of vaginal function. Maturitas 99:10–15. https://doi.org/10.1016/j.maturitas.2017.01.012 CrossRefPubMed

Gambacciani M, Levancini M, Cervigni M (2015) Vaginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause. Climacteric 18:757–763. https://doi.org/10.3109/13697137.2015.1045485 CrossRefPubMedPubMedCentral

Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B, Ali Khan S (2016) Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol 215:704–711. https://doi.org/10.1016/j.ajog.2016.07.045 CrossRefPubMed

Gaspar A, Brandi H, Gomez V, Luque D (2017) Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause. Laser Surg Med 49:160–168. https://doi.org/10.1002/lsm.22569 CrossRef

Hutchinson-Colas J, Segala S (2015) Genitourinary syndrome of menopause and the use of laser therapy. Maturitas 82:342–345. https://doi.org/10.1016/j.maturitas.2015.08.001 CrossRefPubMed

Jelovsek JE, Maher C, Barber MD (2007) Pelvic organ prolapse. Lancet 369:1027–1038CrossRefPubMed

Lang P, Karram M (2017) Lasers for pelvic floor dysfunction: is there evidence? Curr Opin Obstet Gynecol 2017 29(5):354–358. https://doi.org/10.1097/GCO.0000000000000399 CrossRefPubMed

Majaron B, Srinivas SM, Huang HE, Nelson JS (2000) Deep coagulation of dermal collagen with repetetive Er:YAG laser irritation. Lasers Surg Med 26:215–222CrossRefPubMed

Mothes AR, Wanzke L, Radosa MP, Runnebaum IB (2015) Bilateral minimal tension sacrospinous fixation in pelvic organ prolapse: an observational study. Eur J Obstet Gynecol Reprod Biol 188:1–5. https://doi.org/10.1016/j.ejogrb.2015.02.022 CrossRefPubMed

Mothes AR, Radosa MP, Altendorf-Hofmann A, Runnebaum IB (2016) Risk index for pelvic organ prolapse based on established individual risk factors. Arch Gynecol Obstet 293:617–624. https://doi.org/10.1007/s00404-015-3863-2 CrossRefPubMed

Nappi RE, Palacious S (2014) Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 17:3–9. https://doi.org/10.3109/13697137.2013.871696 CrossRefPubMed

Nappi RE, Palacious S, Panay N, Particco M, Krychman ML (2016) Vulvar and vaginalatrophy in four European countries: evidence from the European REVIVE Survey. Climacteric 19:188–197. https://doi.org/10.3109/13697137.2015.1107039

Oyarzun MFG, Castelo-Branco C (2017) Local hormone therapy for genitourinary syndrome of menopause in breast cancer patients: is it safe? Gynecol Endocrinol 33:418–420. https://doi.org/10.1080/09513590.2017.1290076 CrossRefPubMed

Palacios S, Mejia A, Neyro L (2015) Treatment of genitourinary syndrome of menopause. Climacteric 18:23–29. https://doi.org/10.3109/13697137.2015.1079100 CrossRefPubMed

Pieralli A, Fallani MG, Becorpi A, Bianchi C, Corioni S, Longinotti M, Trdici Z, Guaschina S (2016) Fractional CO₂ laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors. Arch Gynecol Obstet 294:841–846. https://doi.org/10.1007/s00404-016-4118-6 CrossRefPubMed

Portman DJ, Gass ML, Vulvovaginal Atrophy Terminology Consensus Conference Panel (2014) Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause Society. Climacteric 17:557–563. https://doi.org/10.3109/13697137.2014.946279 CrossRef

Salvatore S, Nappi RE, Zerbinati N et al (2014) A 12-week treatment with fractional CO₂ laser for vulvovaginal atrophy: a pilot study. Climacteric 17:363–369. https://doi.org/10.3109/13697137.2014.899347 CrossRefPubMed

Santen RJ, Stuenkel CA, Davis SR, Pinkerton JV, Gompel A, Lumsden MA (2017) Managing menopausal symptoms and associated clinical issues in breast cancer survivors. J Clin Endocrinol Metab. https://doi.org/10.1210/jc.2017-01138 (Epub ahead of print)

Santoro N, Komi J (2009) Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 6:2133–2142. https://doi.org/10.1111/j.1743-6109.2009.01335 CrossRefPubMed

Schmitt L, Amann PM, Marquardt Y, Heise R, Czaja K, Gerber PA, Steiner T, Hölzle F, Baron JM (2017) Molecular effects of fractional ablative erbium:YAG laser treatment with multiple stacked pulses on standardized human three-dimensional organotypic skin models. Lasers Med Sci 32:805–814. https://doi.org/10.1007/s10103-017-2175-0 CrossRefPubMed

Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30. https://doi.org/10.3322/caac.2138 CrossRefPubMed

Tadir Y, Gaspar A, Lev-Sagie A, Alexiades M, Alinsod R, Bader A, Calligaro A, Elias JA, Gambaciani M, Gaviria JE, Iglesia CB, Selih-Martinec K, Mwesigwa PL, Ogrinc UB, Salvatore S, Scollo P, Zerbinati N, Nelson JS (2017) Light and energy based therapeutics for genitourinary syndrome of menopause: consensus and controversies. Lasers Surg Med 49:137–159. https://doi.org/10.1002/lsm.22637 CrossRefPubMedPubMedCentral

Vizintin Z, Lukac M, Kazic M, Tettamanti M (2015) Erbium laser in gynecology. Climacteric 18:4–8. https://doi.org/10.3109/13697137.2015.1078668 CrossRefPubMed

Wu JM, Vaughan CP, Goode PS, Redden DT, Burgio KL, Richter HE, Markland AD (2014) Prevalence and trends of symptomatic pelvic floor disorders in US women. Obstet Gynecol 123:141–148. https://doi.org/10.1097/AOG.0000000000000057 CrossRefPubMedPubMedCentral

Titel: Ablative dual-phase Erbium:YAG laser treatment of atrophy-related vaginal symptoms in post-menopausal breast cancer survivors omitting hormonal treatment
verfasst von: A. R. Mothes
M. Runnebaum
I. B. Runnebaum
Publikationsdatum: 27.02.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 5/2018
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2614-8

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Ablative dual-phase Erbium:YAG laser treatment of atrophy-related vaginal symptoms in post-menopausal breast cancer survivors omitting hormonal treatment

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2018

Second primary colorectal cancer among endometrial cancer survivor: shared etiology and treatment sequelae

A study of association of Oncotype DX recurrence score with DCE-MRI characteristics using multivariate machine learning models

Management of elderly women with cervical cancer

NIPA-like domain containing 1 is a novel tumor-promoting factor in oral squamous cell carcinoma

Treatment and outcome of patients with localized intrathoracic and chest wall rhabdomyosarcoma: a report of the Cooperative Weichteilsarkom Studiengruppe (CWS)

Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie